title: EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
abstract: The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes ~600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomized trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programs. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, anogenital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organized approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease.
authors.affiliation: Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. marc.arbyn@wiv-isp.be
authors.forename: Marc
authors.initials: M
authors.lastname: Arbyn
authors.forename: Silvia
authors.initials: S
authors.lastname: de Sanjosé
authors.forename: Mona
authors.initials: M
authors.lastname: Saraiya
authors.forename: Mario
authors.initials: M
authors.lastname: Sideri
authors.forename: Joel
authors.initials: J
authors.lastname: Palefsky
authors.forename: Charles
authors.initials: C
authors.lastname: Lacey
authors.forename: Maura
authors.initials: M
authors.lastname: Gillison
authors.forename: Laia
authors.initials: L
authors.lastname: Bruni
authors.forename: Guglielmo
authors.initials: G
authors.lastname: Ronco
authors.forename: Nicolas
authors.initials: N
authors.lastname: Wentzensen
authors.forename: Julia
authors.initials: J
authors.lastname: Brotherton
authors.forename: You-Lin
authors.initials: YL
authors.lastname: Qiao
authors.forename: Lynnette
authors.initials: L
authors.lastname: Denny
authors.forename: Jacob
authors.initials: J
authors.lastname: Bornstein
authors.forename: Laurent
authors.initials: L
authors.lastname: Abramowitz
authors.forename: Anna
authors.initials: A
authors.lastname: Giuliano
authors.forename: Massimo
authors.initials: M
authors.lastname: Tommasino
authors.forename: Joseph
authors.initials: J
authors.lastname: Monsonego
mesh_terms: D001005:Anus Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D055088:Early Detection of Cancer; D005260:Female; D006258:Head and Neck Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D008297:Male; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D053918:Papillomavirus Vaccines / Q000276:immunology; D010412:Penile Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D011322:Primary Prevention; D055502:Secondary Prevention; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D014846:Vulvar Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy
chemical_list: D053918:Papillomavirus Vaccines